In a recent decision, Delaware’s chief judge expressed confusion over Alnylam Pharmaceuticals’ argument in a patent case involving Pfizer and BioNTech. The biotechnology firm contended that the term “vaccine” in one of its patents, allegedly infringed by Pfizer and BioNTech, did not necessarily imply the presence of an actual vaccine. The judge dismissed this claim, opting instead for what he considered “common sense.” For more details on this ruling, read the article on Law360.